Literature DB >> 26654842

Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort.

Maarten Arends1, Gabor E Linthorst2, Carla E Hollak3, Marieke Biegstraaten4.   

Abstract

Fabry disease (FD) is a progressive, multi-organ, lysosomal storage disease. Enzyme replacement therapy (ERT) is available for the treatment of the disease. While the reasons to initiate ERT have been frequently discussed, discontinuation of ERT is rarely reported. In this paper we describe our experiences with stopping ERT in FD. From 1999 through 2015, twenty-one patients discontinued ERT. These patients were generally older and more severely affected in comparison those who continued ERT. The reason to discontinue ERT switched from death or terminal illness in the first years towards treatment failure in more recent years. Three cases are described in more detail. We conclude that discontinuation of ERT should or may be considered in subgroups of FD patients although further studies on the effectiveness of ERT in subgroups of patients and the course of the disease after discontinuation of ERT are needed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agalsidase; Discontinuation; ERT; Enzyme replacement therapy; Fabry disease

Mesh:

Year:  2015        PMID: 26654842     DOI: 10.1016/j.ymgme.2015.11.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

1.  Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Authors:  Philippe Provençal; Michel Boutin; Shaalee Dworski; Bryan Au; Jeffrey A Medin; Christiane Auray-Blais
Journal:  Bioanalysis       Date:  2016-08-15       Impact factor: 2.681

2.  Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease.

Authors:  Fahad J Alharbi; Shanat Baig; Christiane Auray-Blais; Michel Boutin; Douglas G Ward; Nigel Wheeldon; Rick Steed; Charlotte Dawson; Derralynn Hughes; Tarekegn Geberhiwot
Journal:  J Inherit Metab Dis       Date:  2018-01-02       Impact factor: 4.982

Review 3.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06

4.  Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.

Authors:  Maarten Arends; Marieke Biegstraaten; Derralynn A Hughes; Atul Mehta; Perry M Elliott; Daniel Oder; Oliver T Watkinson; Frédéric M Vaz; André B P van Kuilenburg; Christoph Wanner; Carla E M Hollak
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.